TELFOCUS 40 mg price in UAE

Overview

Welcome to Dwaey, specifically on TELFOCUS 40 mg Tablet page.
This medicine contains an important and useful components, as it consists of Telmisartan.
TELFOCUS 40 mg is available in the market in concentration 40 mg/tablet and in the form of Tablet .

AUROBINDO PHARMA FZ LLC is the producer of TELFOCUS 40 mg and it is imported from UAE, The most popular alternatives of TELFOCUS 40 mg are listed downward .

Mode Of Action

Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. It exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstricting and aldosterone-secreting effects of angiotensin II.

Indication

Hypertension
Diabetic nephropathy

Precaution

Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients.

Side Effects

1-10% Upper respiratory tract infection (URTI) (7%)
Back pain (3%)
Diarrhea (3%)
Myalgia (3%)
Sinusitis (3%)
Chest pain (1%)
Hypertension (1%)
Headache (1%)
Dizziness (1%)
Pharyngitis (1%) <1% Abnormal ECG
Anemia
Angina
Angioedema
Bradycardia
Eczema
Epistaxis
Gout
Hypercholesterolemia
Hyperkalemia
Hypoglycemia
Otitis media Potentially Fatal: Rarely angioedema
rash
pruritus and urticaria.

Contra indication

Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D

Interaction

May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).